论文部分内容阅读
目的观察培美曲塞(PEM)联合顺铂(DDP)治疗晚期肺腺癌的临床疗效及不良反应。方法将52例晚期肺腺癌患者随机分为观察组和对照组各26例,观察组采用PEM(500mg/m2,第1天)+DDP(80mg/m2,第1、2天)全身化疗,对照组采用吉西他滨(GEM)(1000mg/m2,第1、8天)+DDP(80mg/m2,第1、2天)全身化疗。2组均以28d为1个周期,于规则化疗2周期后评估2组临床疗效及不良反应。结果观察组缓解率为34.62%,控制率为76.92%,均高于对照组中的23.08%及57.69%,2组缓解率及控制率比较差异均有统计学意义(P<0.05)。观察组骨髓抑制发生率及消化道症状发生率均低于对照组,差异有统计学意义(P<0.05)。结论采用PEM联合DDP治疗晚期肺腺癌的临床疗效明显优于传统的GEM联合DDP方案,其对骨髓抑制的不良反应低,可明显延缓肿瘤复发,减轻晚期肺腺癌患者的痛苦,提高生活质量。
Objective To observe the clinical efficacy and side effects of pemetrexed (PEM) combined with cisplatin (DDP) in the treatment of advanced lung adenocarcinoma. Methods Totally 52 patients with advanced lung adenocarcinoma were randomly divided into observation group (26 cases) and control group (26 cases). The observation group was treated with PEM (500mg / m2, day 1) + DDP (80mg / m2, The control group received gemcitabine (GEM) (1000 mg / m2, day 1, day 8) + DDP (80 mg / m2, day 1, day 2) for systemic chemotherapy. Two groups were 28d for a cycle, two cycles after the regular chemotherapy to assess the clinical efficacy and adverse reactions in two groups. Results The remission rate was 34.62% in the observation group and the control rate was 76.92%, which were significantly higher than those in the control group (23.08% and 57.69%, respectively). There was significant difference between the two groups in remission rate and control rate (P <0.05). The incidence of myelosuppression and the incidence of gastrointestinal symptoms in the observation group were lower than those in the control group, the difference was statistically significant (P <0.05). Conclusions The clinical efficacy of PEM combined with DDP in the treatment of advanced lung adenocarcinoma is significantly better than that of traditional combined with DDP. The adverse reactions to bone marrow suppression are low, which can significantly delay the recurrence of tumor, relieve the pain of patients with advanced lung adenocarcinoma and improve the quality of life .